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Platelets are a kind of blood cells derived from bone marrow megakaryocytes 
and play essential roles in thrombosis, hemostasis, and tissue repair. Platelets have 
been found to be crucially involved in various immune responses and actively 
involved in the pathogenesis of allergic diseases such as allergic asthma. Patients 
with allergic asthma have lower platelet counts and increased levels of markers of 
platelet activation after allergen exposure. Platelets have been found extravascu-
larly in the airways, and platelet products have been measured in bronchoalveolar 
lavage (BAL) fluid of asthmatic patients. Platelets are also crucially involved in the 
development of allergic diseases, including the development of allergic asthma via 
the regulation of allergic inflammation, especially type 2 inflammation mediated 
by active platelet-derived IL-33 protein activation. Both platelets and IL-33 are 
activated by tissue damage and involved in biological defense mechanisms and 
initiation of tissue repair. Therefore, platelets may be involved in the development 
of steroid-refractory asthma, including irreversible airway remodeling phenotypes.
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1. Introduction
Platelets, also known as thrombocytes (from the Greek words thrombos meaning 
clot and kytos meaning a vessel, i.e., a cell), are blood components with a well-
established role in hemostasis and thrombosis. Platelets are circulating anuclear 
cell fragments ca. 2 μm in diameter derived from megakaryocytes of the bone 
marrow, and their production (as well as megakaryocyte production) is regulated 
by thrombopoietin (also known as megakaryocyte growth and development factor, 
MGDF). About 1011 new platelets are produced daily in a healthy adult individual, 
and the average life span of circulating platelets is up to 10 days. Platelets respond to 
vascular injury by clumping and initiation of blood clotting [1]. More specifically, 
when blood vessels are damaged and bleeding occurs, immediate and appropriate 
actions are required to prevent excessive blood loss and to repair tissue damage, 
including injured blood vessels, and platelets play a central role in these processes. 
The immediate response to vascular injury and bleeding is vasoconstriction, and 
soon after that, platelets, which normally circulate the bloodstream in a quiescent 
state due to certain inhibitory signals, adhere and accumulate at the site of vascular 
endothelium damage. They become activated and release the contents of their 
granules containing adenosine diphosphate (ADP), thromboxane A2 (TXA2), 
calcium, platelet-activating factor (PAF), serotonin, etc. This further promotes 
platelet aggregation and the formation of a temporary and unstable platelet plug 
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in a process referred to as primary hemostasis. The activation of a number of 
coagulation factors leads to the formation of a fibrin mesh which then covers the 
platelet plug, generating a stable fibrin clot (a process called secondary hemo-
stasis). Logically, once their hemostatic function ceases, clots must be degraded 
and removed and the tissue damage at the clot site repaired [2, 3]. Undamaged 
vascular endothelial cells surrounding the clot produce tissue plasminogen activa-
tor (tPA) which catalyzes the conversion of plasminogen to active plasmin, a key 
enzyme involved in clot degradation (fibrinolysis), while the platelets are removed 
by phagocytosis. Additionally, platelets contain a number of cell and transform-
ing growth factors, including transforming growth factor-β (TGF-β), epidermal 
growth factor (EGF), and platelet-derived growth factor (PDGF), which play 
important roles in tissue repair [4].
Since platelets seem to be involved in all processes in response to hemorrhage, 
including primary and secondary hemostasis, fibrinolysis, and tissue repair, it is 
conceivable that they may be critical in maintaining the physical barriers to exter-
nal attacks such as pathogen invasion, including the epithelial barrier integrity 
and function as well as immune responses, and the body of evidence to support 
that theory is growing. Indeed, it seems that platelets function quite differently 
in inflammatory immune responses than they do in hemostasis and thrombosis. 
Moreover, there are specific and distinct physiological signals and mechanisms 
in platelet functions involving aggregation (in hemostasis) and those involving 
immune processes, such as communication and interactions with leukocytes, 
platelet chemotaxis, as well as direct antimicrobial effects [5]. This has led to the 
hypothesis of a dichotomy in platelet activation—coagulation vs. their involvement 
in a plethora of physiologic immune reactions, as well as inflammatory disorders 
including allergic diseases and asthma [6]. A summary of the dual nature of platelet 
functions and activation mechanisms is represented in Figure 1.
2. Platelet function in the innate and acquired immune responses
Other than posing a risk for serious bleeding, vascular injury represents a sig-
nificant risk of pathogen invasion. Hence, in addition to a thrombin clot preventing 
Figure 1. 
Dichotomy of platelet functions and activation. Depending on the type of activation signals and mechanisms 
(prothrombotic or inflammatory), platelets may exhibit either hemostatic and thrombotic (on the right, 
green box) or proinflammatory effects (on the left, purple box). Red objects indicate platelets (quiescent or 
activated), while blue objects represent platelet granules.
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further blood loss, a functional immunological barrier must be formed at the site 
of vascular damage as soon as possible in order to prevent the spreading of bacteria, 
viruses, and other pathogens into the body. Platelets exhibit important functions 
in assisting and directly modulating inflammatory immune responses, which is 
why they can be considered vital contributors to the integrity of the immunological 
barrier. These include mechanisms of both the innate and adaptive immunity.
2.1 Immunothrombosis
Tightly regulated and directed thrombosis (called immunothrombosis) in 
response to vascular injury serves to locally prevent the spread of pathogens to the 
bloodstream. This process is orchestrated in concordance with platelets and other 
immune cells, such as neutrophils and monocytes, and initiated either by classical 
immune cells via their pattern recognition receptors (PRRs) or by the binding of 
platelets to bacteria. Platelets bind to pathogenic bacteria either directly via throm-
bocytic pattern recognition receptors to epitopes on bacterial surface or by other 
plasma proteins that bridge platelets and bacteria [7, 8].
In the process of immunothrombosis, monocytes respond to bacterial pathogen-
associated molecular patterns (PAMPs) or damage-associated molecular patterns 
(DAMPs) by activating extrinsic coagulation pathways with tissue factors (tissue 
thromboplastin).
Additionally, along with their classical phagocytosis function in response to 
pathogen invasion, neutrophils facilitate this process by eliminating pathogens 
by throwing web-like implements or neutrophil extracellular traps (NETs). This 
process is known as NETosis and represents an alternative type of cell death (other 
than apoptosis or necrosis). Neutrophils activated in this manner release nuclear 
DNA and antimicrobial proteins including elastase and myeloperoxidase extracel-
lularly by disrupting their own cell membrane. Pathogens captured by these net-like 
structures are more easily being phagocytosed. In turn, platelets seem to facilitate 
NETosis. Platelets are activated, among other stimuli, by binding lipopolysac-
charide (LPS) on Gram-negative bacteria via the Toll-like receptor-4 (TLR4). Such 
activated platelets express P-selectin (or CD62P), a cell adhesion molecule vital in 
leukocyte recruitment (including neutrophils) to sites of injury via their ligand 
P-selectin glycoprotein ligand-1 (PSGL-1). This signaling pathway further activates 
neutrophils to release larger amounts of NETs, and it seems that platelet-neutrophil 
interactions are essential in the production of NETs since platelet depletion or the 
disruption of platelet-neutrophil interactions resulted in the proliferation and fur-
ther diffusion of bacteria in a murine sepsis model. Moreover, NETs also bind tissue 
factor and activate the intrinsic coagulation pathway by providing its negatively 
charged surface to the coagulation factor XII and thus participate in immunothrom-
bosis [2, 9–17].
2.2 Platelets are immune cells, de facto
Although they are usually viewed as anuclear cell fragments originating from 
megakaryocytes involved in hemostasis and thrombosis, platelets exhibit virtually 
all characteristics of classical immune cells. They contain a number of immune-
associated molecules in their intracellular granules, such as P-selectin stored in 
α-granules in circulating quiescent platelets [18]. When platelets are activated (e.g., 
by thrombin or ADP), P-selectin is immediately translocated to the plasma mem-
brane [19]. There, it acts as a receptor or ligand for its counterpart expressed on the 
surface of other immune cells (PSGL-1), such as neutrophils (as described above), 
monocytes, and lymphocytes, and it is vital for the initiation of the recruitment of 
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these cells to the site of interest [10, 11]. Once activated, platelets secrete a number 
of other immune-associated molecules, such as chemokines, cytokines, lipid media-
tors, and growth factors that modulate the inflammatory immune response at the 
site of vascular injury [4].
Additionally, platelets possess the ability to kill pathogens in both an indirect 
manner (by recruiting other immune cells) and even directly. Indeed, platelets store 
a number of molecules with strong antimicrobial potency in their α-granules called 
platelet microbicidal proteins (PMPs) [20, 21], such as the chemokines CXCL4 (or 
platelet-factor 4, PF-4) and CXCL-7 (or neutrophil-activating peptide-2, NAP-2) 
[22, 23]. When activated and bound to bacteria opsonized by immunoglobulin 
G (IgG), platelets release reactive oxygen species (ROS), antimicrobial peptides, 
defensins, kinocidins, and proteases, thus killing the pathogen directly [24]. 
Moreover, other than their involvement in NETosis-mediated pathogen destruction, 
platelets are involved in other processes directed against microbes involving eosino-
phil functions similar to NETosis. More specifically, eosinophils and even mast cells 
are known to produce extracellular DNA traps similar to NETs (called eosinophil 
extracellular traps, EETs in eosinophils), and certain platelet-derived factors (PAF 
in combination with IL-5 and GM-CSF) may be involved in the induction and 
propagation of EETosis [25]. Platelets also express Toll-like receptors 1 through 4 
(TLR1-4) and TLR6-9, thus facilitating antigen recognition (PAMPs) and innate 
immune responses in pathogen destruction [26, 27].
Platelets also express functional receptors of both high and low affinity for 
immunoglobulins (FcγRI, FcγRII, FcγRIII, FcεRI, FcεRII, FcαRI, etc.) suggesting an 
important role in adaptive immune response. Moreover, activated platelets express 
both CD40 and its ligand (CD40L, CD154), which are crucial in antigen presenta-
tion to effector cells (T lymphocytes) [28]. Platelet-derived CD40L is also involved 
in the maturation and activation of dendritic cells (DCs) even extravascularly [29] 
as well as in the production of T-dependent isotype switching [30].
All of these, along with platelet ability to undergo phagocytosis [31] and che-
motaxis to the tissue of interest, emphasize the vital role of platelets in both innate 
and adaptive immune responses and define them as immune cells de facto. As such, 
platelets are involved in the pathogenesis of a number of immune disorders, includ-
ing allergic inflammation and asthma.
3. Role of platelets in allergic inflammation and bronchial asthma
As mentioned before, since platelets may very well be considered immune cells 
and due to their role in the functioning and integrity of the epithelial and immu-
nological barrier, they are involved in the pathogenesis of a number of chronic 
diseases, including cancer and inflammatory disorders. Platelet abnormalities in 
allergy have long been reported, and numerous studies since have underpinned 
their importance in the regulation of allergic inflammation.
As mentioned before, platelets express both the high- and low-affinity IgE 
receptors on their surface, and moreover, in allergic donors, exposure to the sen-
sitizing allergen leads to the production of a number of inflammatory mediators, 
such as serotonin and CCL5 or “regulated on activation, normal T cell expressed 
and secreted” (RANTES) [32, 33]. In mice with ovalbumin (OVA)-induced allergic 
inflammation, platelets from ovalbumin-sensitized animals, but not those lacking 
the high-affinity IgE receptor, migrated extravascularly to the lungs in response 
to allergic stimuli, thus suggesting that platelets actively participate in antigen-
dependent allergic inflammation, including early phases, and via IgE-mediated 
mechanisms [34].
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Additionally, platelets seem to be important for the recruitment of antigen- 
specific activated T lymphocytes (CD69+ CD4+ T cells) into inflamed airways in 
patients with allergic asthma. Platelets adhere to the vascular endothelial cells in the 
airways, and the protein myosin light-chain 9/12 (Myl9/12) in platelets is released to 
form net-like structures intravascularly. Myl9/12 binds to its ligand on CD69+ T cells 
and aids their extravasation and migration to the inflamed lungs. In an asthma murine 
model, blocking of the Myl9/12-CD69 interaction results in reduced airway eosino-
philia, indicating that platelets may be crucial for antigen-specific T-cell responses [35].
Exposure to the sensitizing allergen leads to platelet activation in patients with 
allergic asthma. This allergen challenge may result in a mild peripheral thrombo-
cytopenia (reduced number of platelets), probably due to localized airway recruit-
ment of platelets and the presence of platelet-leukocyte complexes in the blood. 
Patients with asthma have increased levels of platelet-derived mediators, such as 
PAF-4, β-thromboglobulin (β-TG), RANTES, and thromboxane, both in the periph-
eral blood and bronchoalveolar lavage (BAL) fluid, suggesting increased levels of 
platelet activation. Such platelets are referred to as “exhausted” platelets due to their 
continuous activation in allergic inflammation, which is why allergic patients may 
exhibit a mild hemostatic effect associated with shortened platelet survival time 
and slightly prolonged bleeding time [28]. The role of platelet activation in allergic 
inflammation reflects also in the fact that an elevated number of platelet precursors 
(megakaryocytes) has been found in patients who have died of status asthmaticus 
(an extreme form of asthma exacerbation) [36].
As mentioned before, platelets also produce mitogens, such as TXA2, PDGF, 
EGF, and vascular endothelial growth factor, which promote airway cell prolifera-
tion [37]. Additionally, platelets themselves produce extracellular matrix modifying 
enzymes and thus participate in airway remodeling characteristic in allergic disor-
ders, such as smooth muscle cell hyperplasia and collagen deposition [5]. Platelet 
depletion in a murine allergic model resulted in decreased epithelial thickening, 
smooth muscle thickening, and subepithelial fibrosis [38].
During allergic sensitization, platelets may be activated by the upregulation of 
their expression of CD154 (CD40L), which plays a central role in mediating the 
interactions between APCs and lymphocytes. More specifically, platelet-derived 
CD154 is involved in a number of immune responses, including endothelial cell 
response, T-helper cell priming, and activation of cytotoxic T lymphocytes. In a 
murine OVA-induced allergic asthma model, platelet transfer seemed to promote 
allergic inflammation by enhancing leukocyte infiltration to the affected organ, 
enhancing the production of IgE, and propagating T-helper type 2 (Th2)-mediated 
immune responses. On the other hand, platelet depletion in such mice failed to pro-
mote asthma development, suggesting that CD154 (CD40L) derived from platelets 
is required in the progression of allergic asthma. Moreover, platelets seem to inhibit 
the induction of FoxP3+ regulatory T cells via CD154-mediated mechanisms, which 
further supports the theory of the vital role of platelet CD154 in allergic disease 
progression by polarizing Th2-mediated and modifying (inhibiting) Treg-mediated 
immune responses [39].
In summary, allergic inflammatory stimuli (exposure to a sensitizing allergen) 
leads to specific platelet activation (other than that in hemostasis, supporting the 
theory of the dichotomy in platelet functions): the production of a number of 
inflammatory mediators, such as ROS, RANTES, and 5-hydroxytryptamine (5-HT), 
a potent spasmogen and bronchoconstrictor, and the generation of platelet-leukocyte  
complexes resulting in the activation and migration of inflammatory cells to the 
tissue of interest, thus promoting allergic inflammation and platelet chemotaxis to 
the affected tissue further propagating the inflammatory immune response. This is 
schematically represented in Figure 2.
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4. Role of IL-33 in the immune response
Interleukin-33 (IL-33) is essential in the regulation of innate immune responses, 
and the body of evidence to underpin its vital role in allergic inflammation and 
pathogenesis of allergic disorders is growing. IL-33 is a member of the IL-1 super-
family of cytokines that is expressed on a number of cells, including mast cells, 
DCs, macrophages, fibroblasts, as well as endothelial and epithelial cells. It is a 
ligand for the interleukin 1 receptor-like 1 (IL1RL1) which is highly expressed on 
Th2 cells, mast cells, and group 2 innate lymphocytes (ILC2s) [40]. IL-33 exhibits 
a dual nature in function—it acts as a nuclear factor (binding to DNA) intracel-
lularly and as cytokine extracellularly. As a cytokine, it acts as a potent driver of 
the production of Th2-cytokines, such as interleukin-4 (IL-4) from Th2 cells, mast 
cells, eosinophils, and basophils [41, 42].
Genome-wide association studies (GWAS) have identified the IL33 gene and its 
receptor (IL1RL1/ST2) as susceptibility loci in allergy and asthma [43, 44].
IL-33 acts as  an “alarmin”, a factor rapidly released from damaged tissue 
that serves to alert the immune system of a potential threat of infection. IL-33 is 
released by necrotic cells after tissue injury and subsequently acts on target cells. In 
response to IL-33, ILC2s exhibit a strong antigen-non-specific Th2 inflammatory 
response, suggesting their role in allergy and asthma pathogenesis [2]. ILC2s are 
activated by IL-33 alone or in combination with IL-2 and subsequently produce 
large amounts of type 2 cytokines, such as interleukin-5 (IL-5) and interleukin-13 
(Il-13) [45]. Intranasal administration of IL-33 to mice significantly induced airway 
hyperresponsiveness and type 2 inflammation [46]. Moreover, human airway 
epithelial cells and microvascular endothelial cells in the lung express IL1RL1 and 
respond to IL-33 stimuli which leads to a rapid production of neutrophil-attracting 
chemokines [40]. In hemostasis, platelet-derived IL-33 acts on intact tissue cells in 
proximity of injured blood vessels to produce large amounts of CXCR2 chemokines, 
thus recruiting neutrophils to the site of injury. Activated platelets further act on 
Figure 2. 
A summary of the role of platelets in allergic inflammation, more specifically in asthma pathogenesis, in both 
the sensitization (allergen priming) and subsequent re-exposure phases. APCs, antigen-presenting cells.
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neutrophils to release NETs and stimulate neutrophil migration and phagocytosis 
[2, 40]. Moreover, platelets constitutively express the full length IL-33 and are cru-
cial in the development of papain-induced airway eosinophilia in a murine model 
via an IL-33-dependent mechanism [47].
IL-33 is also thought to accelerate Th17 cell-mediated airway inflammation via 
mast cells [48].
5. Platelet-eosinophil interactions in asthma
In asthmatic patients, eosinophilic inflammation is associated with type 2 
inflammation; therefore, the interactions between eosinophils and platelets dur-
ing allergen exposure may be important for the pathogenesis of allergic asthma. In 
patients with allergic asthma, links in activity between eosinophils and platelets 
have been found. Levels of ECP and P-selectin as markers of activation of eosino-
phils and platelets, respectively, were found and suggested a positive associa-
tion between eosinophils and platelets, which was negatively associated with 
asthma-related quality of life [49]. Ex vivo measurements of eosinophils isolated 
from patients with asthma have shown that they adhere to endothelial cells more 
compared to eosinophils from healthy subjects, and platelets seem to promote this 
adhesion [50]. It is known that the mechanism of interaction between platelets 
and eosinophils is associated with increased expression of adhesion molecules on 
activated cells. Expression of P-selectins on platelets was essential for the recruit-
ment of eosinophils into the lung, following allergen challenge [49]. Soluble 
P-selectins enhanced activation of α4β1-integrin on eosinophils and stimulate 
eosinophil adhesion to vascular cell adhesion molecule-1, in vitro [51]. After antigen 
challenge of asthmatic patients, circulating eosinophils associated with P-selectin 
decreased because of migration of platelet-eosinophil complexes into the lungs [52]. 
In addition to this mechanism, the interaction between platelets and eosinophils 
occurs indirectly via inflammatory mediator release, such as chemokine PF-4 
which is capable of promoting eosinophil-endothelial adhesion due to upregulation 
of adhesion molecules [53]. The relationship between platelets and eosinophils is 
synergistic. Eosinophils release cytokines such as platelet-activating factor (PAF) 
and major basic protein (MBP) which can stimulate and activate platelets [54]. 
A recent study reported that platelet aggregation was inhibited by the eosinophil 
cationic protein (ECP) and eosinophil supernatant [55]. The role of eosinophils in 
platelet aggregation and thrombosis is not yet clear [56]. Certainly there is a thera-
peutic potential in disrupting eosinophil-platelet interactions in asthmatic patients 
inhibiting platelet activation and release of platelet cytokines or platelet interaction 
with other inflammatory cells such as eosinophils. Further research of the interac-
tion between platelets and eosinophils may lead to the design of new therapeutic 
regimes in allergic asthma [5, 47].
6. Conclusions
Due to the multiplicity of their role in the immune response, platelets can 
be considered immune cells de facto, and there is mounting evidence on their 
importance in allergic inflammation and asthma pathogenesis. They contribute 
to all phases of the allergic inflammatory response, including sensitization and 
subsequent functional and structural changes of the affected tissue, thus perpetuat-
ing the chronicity of allergic inflammation. Both platelets and IL-33, an alarmin 
molecule, are vital in the maintenance and integrity of the immunological barrier. 
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Moreover, platelets constitutively express IL-33, providing continuous activation 
signals to target cells, including mast cells and ILCs2, which is crucial in allergic 
inflammation. Consequently, an emerging therapeutic potential in the inhibition of 
platelet-dependent inflammation in asthmatic patients may exist.
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